Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) announced its earnings results on Wednesday. The company reported ($4.46) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.23 million for the quarter.
Decoy Therapeutics Price Performance
DCOY stock traded up $0.19 on Thursday, reaching $3.79. 5,721 shares of the company traded hands, compared to its average volume of 181,348. The firm has a fifty day simple moving average of $5.60 and a 200-day simple moving average of $6.67. The company has a market cap of $2.24 million, a P/E ratio of -0.04 and a beta of 0.64. Decoy Therapeutics has a one year low of $3.51 and a one year high of $86.40.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $30.00.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.
Featured Stories
- Five stocks we like better than Decoy Therapeutics
- Axos Financial Keeps Proving the Digital Banking Model Works
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
- Plug Power Charges Ahead: Margin Expansion Sparks a Rally
- Abercrombie’s Comeback Is a Work in Progress
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
